Novo NordiskSee all their emails

Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026

A real announcement email from Novo Nordisk. Captured June 5, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026 email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces positive phase 2 clinical trial results for investigational drug zenagamtide for type 2 diabetes.

Corporate press release style. Logo at top left. Bulleted summary followed by detailed text blocks, a data table, and contact information. Minimalist layout with high text density.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.